Condition

Hormone Receptor-Positive Breast Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14

Recruiting9

Common interventions20

Lead sponsors shown12

Clinical trials

14 shown

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast CancerNCT07796880 · 2026-09-14

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant TreatmentNCT07366112 · 2026-04-20

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without DiarrheaNCT07264998 · 2025-12-21

Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerNCT07856225 · 2025-12-01

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerNCT06970912 · 2025-08-01

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureNCT07708194 · 2025-06-23

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · 2024-10-30

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdNCT07073755 · 2023-01-01

SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast CancersNCT07844759 · 2027-01-01

NOT_YET_RECRUITING

Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast CancerNCT07833501 · 2026-09-03

NOT_YET_RECRUITING

A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast CancerNCT07294339 · 2026-04-01

NOT_YET_RECRUITING

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerNCT06878248 · 2025-04-17

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaNCT01177397 · 2010-07-20

Common interventions

Leading sponsors

Peking University People's Hospital3 Calibr, a division of Scripps Research1 Celgene1 D'Or Institute for Research and Education1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 Fundación Santa Fe de Bogota1 Hubei Cancer Hospital1 Hunan Cancer Hospital1 Renaissance Institute of Precision Oncology and Radiosurgery1 Rutgers, The State University of New Jersey1 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 Tianjin Medical University Cancer Institute and Hospital1

Trial status mix

RECRUITING9

NOT_YET_RECRUITING3

COMPLETED1

TERMINATED1

Phase mix

PHASE26

PHASE13

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.